Dublin, June 25, 2021 (GLOBE NEWSWIRE) -- The "Global Induced Pluripotent Stem Cells Market: 2021-2026" report has been added to ResearchAndMarkets.com's offering.
This study focuses on the market side of iPSCs rather than its technical side. Different market segments for this emerging market are covered.
Product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis. Application-based market segments include drug development and toxicity testing, academic research, and regenerative medicine. iPSC-derived cell-type-based market segments include hepatocytes, neurons, cardiomyocytes, endothelial cells, and other cell types.
It has been more than 10 years since the discovery of iPSC technology. The market has gradually become an essential part of the life sciences industry in recent years. Since the discovery of iPSCs, a large and growing research product market has grown into existence, mainly because the cells are noncontroversial and can be generated directly from adult cells. iPSCs represent a lucrative market segment because methods for commercializing this cell type are expanding every year, and clinical studies investigating iPSCs are swelling in number.
The reprogramming of human somatic cells into iPSCs offers tremendous potential for cell therapy, primary research, disease modeling, and drug development. Human iPSCs can be generated in culture, expanded, and then used to manufacture clinical-grade cells of almost any adult cell type.
iPSCs are adult stem cells that are isolated and then transformed into embryonic-like stem cells by manipulating gene expression and other methods. Experimentation and research using mouse cells by Shinya Yamanaka's lab at Kyoto University in Japan was the first case in which there was a successful generation of iPSCs. In 2007, a series of follow-up analysis were done at Kyoto University in which human adult cells were transformed into iPSCs. Nearly simultaneously, a research group at the University of Wisconsin-Madison achieved the same feat of deriving iPSC lines from human somatic cells.
Continued analysis and experimentation have resulted in several advances over the last few years. For instance, many independent research groups have announced that they have derived human cardiomyocytes from iPSCs. These cells could be further used in a laboratory setting to test drugs that treat arrhythmia and other cardiac diseases, and in a clinical setting they could potentially be implanted into patients with heart disorders.
Similar advances are continuing on the use of reprogrammed adult cells in the treatment of other diseases and conditions. Original techniques for iPSCs production, such as viral-induced transcription processes, are being substituted with newer technologies as private industry combines with the scientific community to develop safer and more effective methods of iPSCs production.
As innovation methods of iPSCs production continue, clinical-grade production of industrial quantities of iPSCs is now becoming possible due to continued research and experimentation. However, the iPSCs space is still relatively new, and therefore, full of business risks. One of the hurdles involves intellectual property. Because the technology involves manipulating donors' cells, the issue of patenting and ownership of those cells becomes a pressing problem.
Today, a patent license for a method to generate iPSCs might be obsolete when the patent filing is completed. This might be one reason why few companies have yet to commercialize cell lines derived from iPSCs, and they are unsure of how to license or protect their intellectual property.
Despite the uncertainty, a substantial business opportunity exists for companies looking to commercialize iPSCs, due to the high demand for iPSC life science tools. Many companies are in or entering the iPSC space, including some major life science and pharmaceutical players. This is in part because of the value added to the pharmaceutical space through improved drug development. Future applications of iPSCs will go far beyond their use as life science tools, ranging from personalized drugs to regenerative cell therapies.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Key Drivers for Market Growth
Chapter 3 Market Overview
History and Current State
Evolution of Induced Pluripotent Stem Cell Research
Advantages and Disadvantages of Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cell Generation
Induced Pluripotent Stem Cell Differentiation
Current Challenges to iPSC Applications
Chapter 4 Impact of COVID-19 Pandemic
Impact on MedTech
Elective and Noncritical Procedures
Shift in Manufacturing
Regulatory Delays, Clinical Trials and Product Launches
Supply Chain Disruptions
Impact of COVID-19 on iPSCs
Pluripotent Stem Cells as a Study Model for COVID-19
Scientists Use Stem Cells to Uncover COVID-19 Effects on the Heart
Chapter 5 Induced Pluripotent Stem Cell Applications
Drug Discovery and Development
Chapter 6 Induced Pluripotent Stem Cells Market Segmentation and Forecast
Application-Based Market Overview
Induced Pluripotent Stem Cells Product Market
Induced Pluripotent Stem Cell-Derived Tissue Cell Market
Induced Pluripotent Stem Cells and Their Derivative Cell Market by Species
Major Suppliers and Manufacturers of Induced Pluripotent Stem Cell Products
Market for Induced Pluripotent Stem Cell-Derived Cells by Application
Market for Induced Pluripotent Stem Cells by Product Function
Research Market Compared with the Clinical Market
Chapter 7 Induced Pluripotent Stem Cells Research Application Market
Induced Pluripotent Stem Cells Research Product Types
Major Commercial Entities
Major Noncommercial Organizations
Market Shares and Projections
Chapter 8 Induced Pluripotent Stem Cell Contract Service Market
Induced Pluripotent Stem Cell Contract Service Types
Market Shares and Projections
Chapter 9 Research Market Trend Analysis
Scientific Publication Analysis
Chapter 10 Clinical Application Market Trend Analysis
Age-Related Macular Degeneration
Ischemic Heart Disease
Graft-versus-Host Disease (GvHD)
Spinal Cord Injuries
Chapter 11 Competitive Landscape
Mergers and Acquisitions
Chapter 12 Company Profiles
Allele Biotechnology And Pharmaceuticals Inc.
Applied Biological Materials Inc. (Abm)
Applied Stemcell Inc. (Asc)
Axol Bioscience? Ltd.
Bristol-Myers Squibb (Ipierian)
Cell Signaling Technology (Cst)
Fujifilm Cellular Dynamics Inc. (Fcdi)
ID Pharma Co., Ltd.
Lonza Group Ltd.
MTI-Globalstem, A Part Of Thermo Fisher Scientific
Sciencell Research Laboratories
System Biosciences Inc.
Takara Bio Usa Inc. (Clontech Laboratories)
Thermo Fisher Scientific
Chapter 13 Appendix: List of Acronyms
For more information about this report visit https://www.researchandmarkets.com/r/636xim
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900